Table of Contents Author Guidelines Submit a Manuscript
Dermatology Research and Practice
Volume 2012, Article ID 182157, 4 pages
Review Article

Ipilimumab, a Promising Immunotherapy with Increased Overall Survival in Metastatic Melanoma?

1Department of Dermatopathology, University Hospital of Liège, 4000 Lièg, Belgium
2Department of Dermatology, University Hospital of Besançon, 25000 Besançon, France
3University of Franche-Comté, 25000 Besançon, France
4EA3181, IFR133, 25000 Besançon, France
5Inserm U645, IFR133, 25000 Besançon, France

Received 30 May 2011; Accepted 23 August 2011

Academic Editor: Pascale Quatresooz

Copyright © 2012 Gérald E. Piérard et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Malignant melanoma (MM) is one of the most aggressive skin cancer. The therapeutic options remain limited for advanced MM, and those directed to the neoplastic cells have not brought major survival advantage so far. Immunotherapy is another targeted option. Ipilimumab, a monoclonal antibody directed to CTLA-4 present on cytotoxic T cells boosts immunity, particularly its anti-MM activity. Under treatment, the overall survival of patients with MM metastases is moderately but significantly increased. The immuno-related adverse effects may be severe and life threatening.